The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical’s subsidiary, Jiangsu Xingsheng Xinhui Pharmaceutical, has received approval from China’s National Medical Products Administration to conduct clinical trials for XS-03 tablets. These tablets, intended for treating metastatic colorectal cancer with RAS mutations, will be tested in combination with existing standard treatments FOLFOX or FOLFIRI and bevacizumab. The approval marks a significant step in advancing the company’s oncology pipeline and could potentially enhance its positioning in the pharmaceutical industry.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on the development and production of medical products, with a market emphasis on innovative drug development and healthcare services.
YTD Price Performance: 14.20%
Average Trading Volume: 5,317
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.55B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com